CD4 T cells, lymphopenia, and IL-7 in a multistep pathway to autoimmunity

被引:107
作者
Calzascia, Thomas [1 ]
Pellegrini, Marc [1 ]
Lin, Albert [1 ]
Garza, Kristine M. [1 ]
Elford, Alisha R. [1 ]
Shahinian, Arda [1 ]
Ohashi, Pamela S. [1 ]
Mak, Tak W. [1 ]
机构
[1] Univ Hlth Network, Campbell Family Inst Breast Canc Res, Toronto, ON M5G 2C1, Canada
关键词
lymphocyte homeostasis; CD8 T cells; cytokines; dendritic cells; cyclophosphamide;
D O I
10.1073/pnas.0712135105
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
There are many inhibitory mechanisms that function at the cellular and molecular levels to maintain tolerance. Despite this, self-reactive clones escape regulatory mechanisms and cause autoimmunity in certain circumstances. We hypothesized that the same mechanisms that permit T cells to expand during homeostatic proliferation may inadvertently promote autoimmunity under certain conditions. One major homeostatic cytokine is IL-7, and studies have linked it or its receptor to the development of multiple sclerosis and other autoimmune diseases. We show in a model of P-islet cell self-reactivity that the transfer of activated autoreactive CD4 T cells can prime and expand endogenous autoreactive CD8 T cells in a CD28- and CD40-dependent manner through the licensing of dendritic cells. Despite this, mice do not develop diabetes. However, the provision of exogenous IL-7 or the physiological production of IL-7 associated with lymphopenia was able to profoundly promote the expansion of self-reactive clones even in the presence of regulatory T cells. Autoimmune diabetes rapidly ensued with CD4 help and the subsequent activation of CD8 T cells, which contributed to disease progression. With the advent of many biologicals targeting TNF alpha, IL-6, and IL-1 and their effective use in the treatment of autoimmune diseases, we propose that IL-7 and its receptor may be promising targets for biological agents in the treatment of autoimmunity.
引用
收藏
页码:2999 / 3004
页数:6
相关论文
共 46 条
[11]   CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative [J].
Ghiringhelli, F ;
Larmonier, N ;
Schmitt, E ;
Parcellier, A ;
Cathelin, D ;
Garrido, C ;
Chauffert, B ;
Solary, E ;
Bonnotte, B ;
Martin, F .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2004, 34 (02) :336-344
[12]   TRANSGENIC MICE THAT EXPRESS A MYELIN BASIC PROTEIN-SPECIFIC T-CELL RECEPTOR DEVELOP SPONTANEOUS AUTOIMMUNITY [J].
GOVERMAN, J ;
WOODS, A ;
LARSON, L ;
WEINER, LP ;
HOOD, L ;
ZALLER, DM .
CELL, 1993, 72 (04) :551-560
[13]   A FAIL-SAFE MECHANISM FOR MAINTAINING SELF-TOLERANCE [J].
GUERDER, S ;
MATZINGER, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (02) :553-564
[14]   Interleukin-7 induced immunopathology in arthritis [J].
Hartgring, S. A. Y. ;
Bijlsma, J. W. J. ;
Lafeber, F. P. J. G. ;
van Roon, J. A. G. .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 :69-74
[15]   GENETIC DISSECTION OF AUTOIMMUNE TYPE-I DIABETES IN THE BB RAT [J].
JACOB, HJ ;
PETTERSSON, A ;
WILSON, D ;
MAO, Y ;
LERNMARK, A ;
LANDER, ES .
NATURE GENETICS, 1992, 2 (01) :56-60
[16]   CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes [J].
Janssen, EM ;
Lemmens, EE ;
Wolfe, T ;
Christen, U ;
von Herrath, MG ;
Schoenberger, SP .
NATURE, 2003, 421 (6925) :852-856
[17]   FOLLOWING A DIABETOGENIC T-CELL FROM GENESIS THROUGH PATHOGENESIS [J].
KATZ, JD ;
WANG, B ;
HASKINS, K ;
BENOIST, C ;
MATHIS, D .
CELL, 1993, 74 (06) :1089-1100
[18]   Homeostatic expansion of T cells during immune insufficiency generates autoimmunity [J].
King, C ;
Ilic, A ;
Koelsch, K ;
Sarvetnick, N .
CELL, 2004, 117 (02) :265-277
[19]   Autoimmunity during lymphopenia: A two-hit model [J].
Krupica, Tom, Jr. ;
Fry, Terry J. ;
Mackall, Crystal L. .
CLINICAL IMMUNOLOGY, 2006, 120 (02) :121-128
[20]   CD4+ T cell help impairs CD8+ T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity [J].
Kurts, C ;
Carbone, FR ;
Barnden, M ;
Blanas, E ;
Allison, J ;
Heath, WR ;
Miller, JFAP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (12) :2057-2062